论文部分内容阅读
目的观察人血白蛋白联合呋塞米治疗肝硬化难治性腹水的效果。方法选取医院收治的肝硬化难治性腹水患者34例作为研究对象,在患者知情同意下由临床医师采取等距随机抽样法分为观察组和对照组各17例,对照组给予呋塞米进行治疗,观察组在对照组治疗基础上给予人血白蛋白。比较2组临床疗效和不良反应。结果观察组治疗总有效率为94.12%高于对照组的58.82%,差异有统计学意义(P<0.05)。观察组的恶心、呕吐、腹胀各项不良反应发生率及总发生率均低于对照组,差异均有统计学意义(P<0.05)。结论采用人血白蛋白联合呋塞米治疗肝硬化难治性腹水,能够提高疗效,有效减少患者不良反应发生,具有一定的临床应用价值。
Objective To observe the effect of human serum albumin combined with furosemide in treatment of refractory ascites caused by cirrhosis. Methods Totally 34 patients with cirrhosis refractory ascites admitted to hospital were enrolled in this study. The patients were divided into observation group and control group with 17 patients in the observation group and control group by equidistant random sampling with informed consent. The control group was given furosemide Treatment, observation group given in the control group on the basis of human serum albumin. The clinical efficacy and adverse reactions in two groups were compared. Results The total effective rate of the observation group was 94.12% higher than that of the control group (58.82%), the difference was statistically significant (P <0.05). The incidence of nausea, vomiting and abdominal distension in observation group were lower than those in control group (P <0.05). Conclusion The treatment of cirrhosis-refractory ascites with human serum albumin combined with furosemide can improve the curative effect and effectively reduce the occurrence of adverse reactions in patients, and has certain clinical value.